Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau)
ABSTRACT Objective While statins have demonstrated a variety of antineoplastic effects in preclinical studies, several retrospective clinical studies and observational studies have not shown a consistent chemopreventive benefit against prostate cancer (PCa). Therefore, in this population‐based cohor...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70485 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841543393511997440 |
|---|---|
| author | Alkiviadis Papagiannakis Maciej Kwiatkowski Stephen F. Wyler Ashkan Mortezavi Lukas Manka Marian S. Wettstein Rainer Grobholz Angelika Hammerer‐Lercher Daniel Eberli Lukas Werner Prause |
| author_facet | Alkiviadis Papagiannakis Maciej Kwiatkowski Stephen F. Wyler Ashkan Mortezavi Lukas Manka Marian S. Wettstein Rainer Grobholz Angelika Hammerer‐Lercher Daniel Eberli Lukas Werner Prause |
| author_sort | Alkiviadis Papagiannakis |
| collection | DOAJ |
| description | ABSTRACT Objective While statins have demonstrated a variety of antineoplastic effects in preclinical studies, several retrospective clinical studies and observational studies have not shown a consistent chemopreventive benefit against prostate cancer (PCa). Therefore, in this population‐based cohort study, we examined the association of statin intake on prostate specific antigen (PSA) values and risk of development of PCa. Method N = 4,314 men from the Swiss section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) were evaluated. N = 761 men were statin users [Stat+]. The median follow‐up was 9.6 years. A transrectal prostate biopsy was performed in men with a PSA‐level ≥ 3 ng/mL. Mortality and incidence data was obtained through registry linkages. PCa incidence, total serum PSA level, free‐to‐total PSA level, and overall survival were compared between [Stat+] and [Stat−] patients. Results Total PSA values were significantly lower in [Stat+] patients at baseline (1.5 vs. 1.8 ng/mL, p < 0.001) and at last follow‐up (1.8 vs. 2.1 ng/mL, p < 0.001). PCa detection during the follow‐up period was significantly associated with baseline PSA. The overall incidence of PCa showed no statistical difference among [Stat+] and [Stat−] groups (7.4% vs. 9.5%, p = 0.08), indicating that statin use had no effect on the risk of developing PCa during follow‐up. [Stat+] patients had a significantly higher overall mortality risk compared to [Stat−] patients (HR 2.04, p < 0.001). Discussion A significant risk reduction in the development of PCa in [Stat+] patients was not found. We did observe lower PSA values among [Stat+] patients, compared to [Stat−] patients, with an increasing difference during follow‐up. |
| format | Article |
| id | doaj-art-241ef97ffa1c42d98cec5c5413450d37 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-241ef97ffa1c42d98cec5c5413450d372025-01-13T13:22:38ZengWileyCancer Medicine2045-76342025-01-01141n/an/a10.1002/cam4.70485Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau)Alkiviadis Papagiannakis0Maciej Kwiatkowski1Stephen F. Wyler2Ashkan Mortezavi3Lukas Manka4Marian S. Wettstein5Rainer Grobholz6Angelika Hammerer‐Lercher7Daniel Eberli8Lukas Werner Prause9Department of Urology Cantonal Hospital Aarau Aarau SwitzerlandDepartment of Urology Cantonal Hospital Aarau Aarau SwitzerlandDepartment of Urology Cantonal Hospital Aarau Aarau SwitzerlandDepartment of Urology University Hospital Zurich Zurich SwitzerlandDepartment of Urology Academic Hospital Braunschweig Braunschweig GermanyDepartment of Surgery, Division of Urology University of Toronto Toronto CanadaCantonal Hospital Aarau Institute of Pathology Aarau SwitzerlandCantonal Hospital Aarau Institute of Laboratory Medicine Aarau SwitzerlandDepartment of Urology University Hospital Zurich Zurich SwitzerlandDepartment of Urology Cantonal Hospital Aarau Aarau SwitzerlandABSTRACT Objective While statins have demonstrated a variety of antineoplastic effects in preclinical studies, several retrospective clinical studies and observational studies have not shown a consistent chemopreventive benefit against prostate cancer (PCa). Therefore, in this population‐based cohort study, we examined the association of statin intake on prostate specific antigen (PSA) values and risk of development of PCa. Method N = 4,314 men from the Swiss section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) were evaluated. N = 761 men were statin users [Stat+]. The median follow‐up was 9.6 years. A transrectal prostate biopsy was performed in men with a PSA‐level ≥ 3 ng/mL. Mortality and incidence data was obtained through registry linkages. PCa incidence, total serum PSA level, free‐to‐total PSA level, and overall survival were compared between [Stat+] and [Stat−] patients. Results Total PSA values were significantly lower in [Stat+] patients at baseline (1.5 vs. 1.8 ng/mL, p < 0.001) and at last follow‐up (1.8 vs. 2.1 ng/mL, p < 0.001). PCa detection during the follow‐up period was significantly associated with baseline PSA. The overall incidence of PCa showed no statistical difference among [Stat+] and [Stat−] groups (7.4% vs. 9.5%, p = 0.08), indicating that statin use had no effect on the risk of developing PCa during follow‐up. [Stat+] patients had a significantly higher overall mortality risk compared to [Stat−] patients (HR 2.04, p < 0.001). Discussion A significant risk reduction in the development of PCa in [Stat+] patients was not found. We did observe lower PSA values among [Stat+] patients, compared to [Stat−] patients, with an increasing difference during follow‐up.https://doi.org/10.1002/cam4.70485chemopreventionERSPCprostate cancerprostate‐specific antigenscreeningstatins |
| spellingShingle | Alkiviadis Papagiannakis Maciej Kwiatkowski Stephen F. Wyler Ashkan Mortezavi Lukas Manka Marian S. Wettstein Rainer Grobholz Angelika Hammerer‐Lercher Daniel Eberli Lukas Werner Prause Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau) Cancer Medicine chemoprevention ERSPC prostate cancer prostate‐specific antigen screening statins |
| title | Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau) |
| title_full | Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau) |
| title_fullStr | Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau) |
| title_full_unstemmed | Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau) |
| title_short | Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau) |
| title_sort | influence of regular statin intake on prostate specific antigen values prostate cancer incidence and overall survival in a prospective screening trial erspc aarau |
| topic | chemoprevention ERSPC prostate cancer prostate‐specific antigen screening statins |
| url | https://doi.org/10.1002/cam4.70485 |
| work_keys_str_mv | AT alkiviadispapagiannakis influenceofregularstatinintakeonprostatespecificantigenvaluesprostatecancerincidenceandoverallsurvivalinaprospectivescreeningtrialerspcaarau AT maciejkwiatkowski influenceofregularstatinintakeonprostatespecificantigenvaluesprostatecancerincidenceandoverallsurvivalinaprospectivescreeningtrialerspcaarau AT stephenfwyler influenceofregularstatinintakeonprostatespecificantigenvaluesprostatecancerincidenceandoverallsurvivalinaprospectivescreeningtrialerspcaarau AT ashkanmortezavi influenceofregularstatinintakeonprostatespecificantigenvaluesprostatecancerincidenceandoverallsurvivalinaprospectivescreeningtrialerspcaarau AT lukasmanka influenceofregularstatinintakeonprostatespecificantigenvaluesprostatecancerincidenceandoverallsurvivalinaprospectivescreeningtrialerspcaarau AT marianswettstein influenceofregularstatinintakeonprostatespecificantigenvaluesprostatecancerincidenceandoverallsurvivalinaprospectivescreeningtrialerspcaarau AT rainergrobholz influenceofregularstatinintakeonprostatespecificantigenvaluesprostatecancerincidenceandoverallsurvivalinaprospectivescreeningtrialerspcaarau AT angelikahammererlercher influenceofregularstatinintakeonprostatespecificantigenvaluesprostatecancerincidenceandoverallsurvivalinaprospectivescreeningtrialerspcaarau AT danieleberli influenceofregularstatinintakeonprostatespecificantigenvaluesprostatecancerincidenceandoverallsurvivalinaprospectivescreeningtrialerspcaarau AT lukaswernerprause influenceofregularstatinintakeonprostatespecificantigenvaluesprostatecancerincidenceandoverallsurvivalinaprospectivescreeningtrialerspcaarau |